Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Assets: 2017-2024

Historic Other Non-Current Assets for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $3.1 million.

  • Aclaris Therapeutics' Other Non-Current Assets fell 11.91% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 11.91%. This contributed to the annual value of $3.1 million for FY2024, which is 26.26% down from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Other Non-Current Assets is $3.1 million, which was down 26.26% from $4.2 million recorded in FY2023.
  • Over the past 5 years, Aclaris Therapeutics' Other Non-Current Assets peaked at $4.5 million during FY2020, and registered a low of $2.7 million during FY2022.
  • Over the past 3 years, Aclaris Therapeutics' median Other Non-Current Assets value was $3.1 million (recorded in 2024), while the average stood at $3.3 million.
  • In the last 5 years, Aclaris Therapeutics' Other Non-Current Assets soared by 52.20% in 2023 and then fell by 26.26% in 2024.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Other Non-Current Assets stood at $4.5 million in 2020, then decreased by 21.27% to $3.6 million in 2021, then fell by 23.13% to $2.7 million in 2022, then surged by 52.20% to $4.2 million in 2023, then decreased by 26.26% to $3.1 million in 2024.